



Moderator: [Harry Glorikian](#), General Partner, New Ventures Funds, Author, *MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market*

Data Management Strategies to Effectively Use AI Tools	
September 15, 2020	
10:45 - 11:15	<p>Convergence and Critical Mass: The Fusion Moment for Biopharma and Data Brian S. Martin, Head of AI R&D Information Research, Research Fellow, AbbVie</p> <p>The AbbVie Research Convergence Hub data sharing program between organizations was launched to correlate all R&D pipeline data, discovery data, RWD, and clinical patient data in a knowledge graph form that takes out the chemical compounds and then make it available to all (pharma, startups, universities). The goal is to create an open data science share that will ultimately help patients.</p>
11:15 - 11:50	<p>Data Curation and Privacy Belen Fraile, MD, MSc, VP & Head, US Oncology Strategic Data & Digital, Novartis Oncology Anna Langhorne, PhD, Esq, Global Data Privacy Counsel, Regeneron Pharmaceuticals, Inc.</p>
11:50 - 12:15	<p>Using AI to Generate Patient Data: How Digital Twins are Shaping Clinical Trials Charles Fisher, PhD, Founder and CEO, Unlearn.AI</p> <p>Digital twins are AI-generated placebo patient data perfectly matched to actual trial patients. With a universal goal of being able to run better and faster clinical trials, this session will use an Alzheimer's use case to demonstrate how digital twins can ultimately result in increased confidence in trial results.</p>
12:15 - 1:15	<p>Drug Development Using RWE, Integrated Research Platforms and Advanced Analytics/AI Thomas Bock, MD, MBA, Founder & Past CEO, HeritX, Inc., Chair, Healthcare Advisory Board, Columbia Business School; Former SVP, Global Head of Medical Affairs, Alexion; Co-Founder, The APANDEMIC Initiative Ülo Palm, MD, PhD, Chief Medical Officer and Co-Founder, Ordaos Bio; Co-Founder The APANDEMIC Initiative Peter Pitts, President and Co-Founder, Center for Medicine in the Public Interest; Former Associate Commissioner for External Relations, FDA, Visiting Professor, Université Paris Descartes Medical School, Chair of Innovation Management & Healthcare Performance</p> <p>An interactive discussion examining the opportunities created when AI tools/technologies and digital platforms are used to evaluate global data in real time:</p> <ul style="list-style-type: none"> • Revisiting the old science of the 'parallel line' • Getting to what a drug works on, who it works on and the level of disease it works on using advanced analytics to evaluate the diversity of patients of whole population • Applying AI in regulatory oversight: How regulatory centaurs present a real opportunity for faster and more accurate drug reviews

Part two of the series is continued on the next page

AI Case Studies in Discovery & Clinical Development	
October 26, 2020	
10:30 - 11:00	<p>Target Identification, Validation & Molecule Generation Martin Akerman, CTO, Envisagenics Spyro Mousses, CEO, Systems Oncology</p>
11:00 - 11:30	<p>How to Approach Predictive Toxicity Modeling Barun Bhatati, Investigator, Novartis Institutes for Bio Medical Research (NIBR) Marcel Hop, Vice President, Genentech</p> <ul style="list-style-type: none"> • Tested AI/ML approaches applied in ADME Tox to complement experimental methods • Use Cases of the benefits of applying data analytics in pre-clinical ADMET programs • Retrospective analysis of results in predictive potency
11:30 - 11:45	<p>Spotlight Presentations Good Machine Learning Practices and Predictive Biomarkers in Clinical Development Rafael Rosengarten, PhD, CEO, Genialis Leveraging AI to Aggregate Healthcare Data and HCP Data Ariel Katz, Co-Founder, H1</p>
11:45 - 12:30	<p>Leader Perspectives in Clinical Development: Achieving Consistency in Validating & Operationalizing the AI/ML Automation Efforts Transforming Biopharma Neal Grabowski, MEng, MBA, Director, Safety Data Science, AbbVie (moderator) Danielle Abatemarco, Scientific Publications Lead, WorldWide Patient Safety, Bristol-Myers Squibb Andrew Bate, PhD, Head of Safety Innovation & Analytics, GSK Jeneen Donadeo, Senior Director, Portfolio Management, TransCelerate BioPharma, Inc.</p> <p>Although certain intelligent automation technologies have been used in some PV areas for years (e.g., rule-based software, auto-coding, auto-narrative generation, etc.), rapid development of newer technologies (e.g., machine learning, natural language processing) has outpaced some PV regulations. Therefore, continued innovation will be more likely and ultimately more successful if companies and 3rd party developers can be reasonably assured they have adequately validated their systems and automated processes. This session will feature a panel of leaders discussing emerging forces that are shaping the global future of biopharma, and how intelligent automation and AI is transforming how we work. The session will include discussions on the current technology landscape in biopharma, particularly in pharmacovigilance; intelligent automation opportunities in PV; and propose consideration for validating intelligent automation technologies in PV to promote inspection readiness and inform third-party development.</p>
12:30 - 1:00	<p>AI and Quantum Computing Approaches to Analysis of Multi-omic Data Thomas W. Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, Genuity Science</p>

About the AI in Biopharma Digital Series

Connecting biopharma's science and technology is what we do best at AI in Biopharma. We provide a unique opportunity to get past the frequently similar headlines of daily newsletters and canned presentations. Interview style sessions led by an experienced and knowledgeable moderator guarantee that you will hear thought-provoking information from industry experts that you won't hear anywhere else.

The AI in Biopharma Digital Events provide the same high value experience that attendees have had for three years at the in-person AI Applications in Biopharma Summit. We respect your time and our focus is on curating content and confirming industry speakers with diverse expertise. This focus on quality content is designed to ensure that your participation will provide new insights, new connections, and practical information to help you do things better and do better things. <https://ai-inbiopharma.com/#digitalseries>

Contact the AI in Biopharma Co-Founders with questions or suggestions

For content and speaking questions, contact Debra Chipman: dchipman@coreylanepartners.com
For sponsorship information, contact Elizabeth Cutler: ecutler@coreylanepartners.com